• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 548906 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1414681215 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1414681215 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Investors look to Lighten Up on Shares of Cytori Therapeutics, Shares Down 5.7% (CYTX)

Published on Fri, 08/09/2013 - 12:38
By Peter Chu

Cytori Therapeutics (NASDAQ:CYTX) is one of today's worst performing low-priced stocks, down 5.7% to $2.50 on 1.3x average daily volume. Cytori Therapeutics has traded 281,000 shares thus far today, vs. average volume of 211,000 shares per day. The stock has underperformed the Dow (-5.7% to the Dow's -0.6%) and underperformed the S&P 500 (-5.7% to the S&P's -0.3%) during today's trading.

Cytori Therapeutics, Inc. discovers and develops cell-based therapeutics utilizing adult stem cells derived from fat tissue. The Company's investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery.

Over the past year, Cytori Therapeutics has traded in a range of $2.20 to $4.93 and is now at $2.50, 14% above that low. The 200-day and 50-day moving averages have moved 1.18% lower and 0.47% higher over the past week, respectively.

Cytori Therapeutics (NASDAQ:CYTX) has potential upside of 165.0% based on a current price of $2.50 and analysts' consensus price target of $6.62. Cytori Therapeutics shares should encounter resistance at the 200-day moving average (MA) of $2.82 and support at the 50-day MA of $2.49.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Investors look to Lighten Up on Shares o...

Ceragon Networks (NASDAQ:CRNT) is one of today's worst performing low-priced stocks, do ...

Rockwell Automation (ROK) Approaches New...

Shares of Rockwell Automation (NYSE:ROK) opened today below their pivot of $109.57 and ...

Integrys Energy (TEG) Crosses Pivot Poin...

Shares of Integrys Energy (NYSE:TEG) opened today above their pivot of $70.34 and have ...

Next Support Level for Lorillard (LO) is...

Shares of Lorillard (NYSE:LO) have bearishly opened below the pivot of $61.14 today and ...

Dr Pepper Snapple (DPS) Approaches New U...

Shares of Dr Pepper Snapple (NYSE:DPS) opened today above their pivot of $67.72 and hav ...

VeriSign (VRSN) Breaks Through Support a...

Shares of VeriSign (NASDAQ:VRSN) opened today below their pivot of $58.78 and have alre ...

DTE Energy (DTE) Crosses Pivot Point Res...

DTE Energy (NYSE:DTE) has opened bullishly above the pivot of $80.15 today and has reac ...

Sempra Energy (SRE) Crosses Pivot Point ...

Sempra Energy (NYSE:SRE) has opened bullishly above the pivot of $108.55 today and has ...